by OTMS Staff | Feb 25, 2026 | PatentVest Pulse
Author: Tyler Teske Wegovy and Zepbound (semaglutide, tirzepatide) built a $71 billion market by treating less than 5% of eligible patients. The other 95% remain untreated, not because the drugs don’t work, but because needles, cold chains, and $1,000-per-month...
by OTMS Staff | Oct 20, 2025 | PatentVest Pulse
A Strategic and IP-Centric Analysis of the Cardiac Diagnostics Ecosystem Authors: Tyler Teske, Will Rosellini Highlights Cardiac Diagnostics Are at an Inflection Point. The tools once confined to hospitals are moving into everyday life, transforming how heart...
by OTMS Staff | Aug 25, 2025 | PatentVest Pulse
Unveiling the Future of Deep Tech Innovation Author: Will Rosellini | [email protected] Executive Summary Artificial intelligence (AI) is fundamentally reshaping the software industry, commoditizing traditional development processes and eroding the...
by OTMS Staff | Aug 18, 2025 | PatentVest Pulse
Authors: Tyler Teske, Will Rosellini, Oscar Chow, Viviana Belloso Highlights The Quantum Inflection Point: Quantum computing is on the brink of unleashing a once-in-a-generation technology shift-one that will reshape industries, national security, and...
by OTMS Staff | May 10, 2025 | PatentVest Pulse
Authors: Tyler Teske, Will Rosellini, Marcelo Forgas 1.0 Highlights Figure AI: Raised over $750M, seeking a $39.5B valuation, yet holds only two patent filings. Most capitalized, yet one of the least defensible from an IP standpoint. Sanctuary AI: Clear category...
by Staff | Mar 31, 2025 | PatentVest Pulse
Authors: Tyler Teske, Will Rosellini, Oscar Chow Highlights $400B+ Market, But Not for Everyone: The U.S. brain-computer interface (BCI) market is real—and enormous. But most of that value will be captured by a small number of companies that move early to secure...
Recent Comments